Navigation Links
Reportlinker Adds Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

IntroductionAs branded angiotensin receptor blockers (ARBs) lose market exclusivity, fixed-dose combinations become the only remaining products able to generate growth in the antihypertensives market. However, they will not be able to do enough to prevent market erosion which will fall from $37.5 billion in 2009 to $28.6 billion in 2019 at -3% CAGR.

Features and benefits

* Analysis of revenue and volume sales of antihypertensive drug classes in the seven major markets* Assess the impact of key patent expiries, such as Merck & Co's Cozaar and Hyzaar* Forecast antihypertensive revenue and volume sales to 2019, including performance of developmental agents* Understand the impact of clinical trials and pipeline agents on future market dynamics

HighlightsThe first triple drug combination; Exforge HCT (valsartan + amlodipine + hydrochlorothiazide) has reached the US market. Valturna (aliskiren + valsartan; Novartis) has combined the direct renin inhibitor aliskiren with the ARB valsartan to become the first drug to offer dual blockade of the renin angiotensin system.The only innovative antihypertensive agent expected to launch by 2019 is Takeda's ARB; azilsartan medoxomil (TAK-491). Launching in this time frame will make azilsartan an extremely late entry to the ARB class and the drug is going to experience of number of resistors to success.Japan has seen a number of recent launches of ARB combinations. If the new launches replicate the success of Hyzaar (launched in 2006) and Japanese physicians accept the ARB + CCB (calcium channel blocker) combination this will represent the strongest opportunity for class growth in the seven major markets.

Your key questions answered* Quantify and qualify antihypertensive sales in each of the seven major markets for 2006–2019* Examine the future performance of leading antihypertensive brands and how the growth of generics will impact revenues* Understand challenges faced by pipeline agents and new fixed-dose-combinations

To order this report:: Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/18/2017)... Pa. and KALAMAZOO, Mich. , Sept. 18, ... , and OptiMed Specialty Pharmacy of ... to offer a strategic hub service that expedites and ... sought-after personal spirometer, Spiro PD 2.0, and wellness management ... spirometer is a medical device used to measure lung ...
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):